Harmony Biosciences’ (HRMY) Buy Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC restated their buy rating on shares of Harmony Biosciences (NASDAQ:HRMY – Free Report) in a report published on Thursday morning, Benzinga reports. Needham & Company LLC currently has a $53.00 price target on the stock. Other equities analysts have also recently issued reports about the stock. Mizuho raised their price target […]
More Stories
Critical Review: i-80 Gold (IAUX) & Its Rivals
i-80 Gold (NYSE:IAUX – Get Free Report) is one of 114 publicly-traded companies in the “Gold & silver ores” industry,...
Hillman Solutions Corp (NASDAQ:HLMN) Receives $14.20 Average Target Price from Analysts
Hillman Solutions Corp (NASDAQ:HLMN – Get Free Report) has earned an average rating of “Moderate Buy” from the six ratings...
Equity Residential (NYSE:EQR) Receives Consensus Rating of “Hold” from Analysts
Equity Residential (NYSE:EQR – Get Free Report) has been assigned a consensus rating of “Hold” from the nineteen brokerages that...
Comparing NLS Pharmaceutics (NASDAQ:NLSP) and Atossa Therapeutics (NASDAQ:ATOS)
Atossa Therapeutics (NASDAQ:ATOS – Get Free Report) and NLS Pharmaceutics (NASDAQ:NLSP – Get Free Report) are both small-cap medical companies,...
Contrasting Globalstar (GSAT) & Its Rivals
Globalstar (NYSEARCA:GSAT – Get Free Report) is one of 32 publicly-traded companies in the “Communication services, not elsewhere classified” industry,...
Head-To-Head Contrast: AIM ImmunoTech (NYSE:AIM) versus INmune Bio (NASDAQ:INMB)
INmune Bio (NASDAQ:INMB – Get Free Report) and AIM ImmunoTech (NYSE:AIM – Get Free Report) are both small-cap medical companies,...